Cencora, Inc.COR
Cencora, Inc. Financial Overview 2021–2025
Cencora's revenue engine is being supercharged by a single therapeutic category, with sales of GLP-1 diabetes and weight-loss medications surging 26.9% to hit a staggering $7.7 billion in FY2025. This explosive volume underscores a clear investment thesis: the company has successfully transformed from a traditional distributor burdened by opioid liabilities into a high-growth specialty care powerhouse.
The long-term trajectory highlights consistent top-line expansion, as revenue grew from $213.99 billion in FY2021 to $321.3 billion in FY2025. This scale was achieved through organic U.S. demand and aggressive consolidation, including the $5.7 billion acquisition of Retina Consultants of America. While these moves drove gross profit up 15.8% to $11.5 billion in FY2025, they also brought operational friction. A massive $723.9 million goodwill impairment tied to its PharmaLex unit pushed operating expenses up 14.4% in the latest fiscal year. Furthermore, Cencora continues to service billions in historical opioid settlements, requiring substantial new debt to fund its ongoing M&A strategy.
The market has aggressively rewarded this pivot toward specialty and international markets. At the close of FY2025, Cencora commanded a $60.6 billion market capitalization and traded at $312.53 per share. This resulted in a premium 39.3x earnings multiple, reflecting high investor confidence in its specialized distribution model despite rising net interest expenses.
Recent Developments (Q4 2025 and Q1 2026)
Cencora aggressively reshaped its portfolio in Q1 2026, pivoting further into human specialty care while shedding non-core assets. In February 2026, the company closed a $4.6 billion acquisition of a majority stake in OneOncology, funded partially by a new $3.0 billion senior notes offering. Concurrently, Cencora agreed to merge its MWI Animal Health division with Covetrus at a $3.5 billion enterprise value, expected to yield $1.25 billion in upfront cash. These moves accompanied a resilient Q1 2026 earnings print, with revenue expanding 5.5% year-over-year to $85.9 billion and net income reaching $559.6 million.
Bulls assert the OneOncology buyout establishes a highly profitable moat within the independent oncology practice sector. Conversely, bears caution against mounting financial risk, noting total debt expanded to $7.9 billion and the stock appeared richly valued at 41.5x earnings as of the Q1 2026 report date.
What to watch: closure of the Covetrus animal health merger and utilization of cash proceeds; operational integration of OneOncology alongside its impact on overall segment margins.
Rev
$321.33B
FY2025
NI
$1.55B
FY2025
EPS
$8.02
FY2025
OCF
$3.88B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
Cencora, Inc. 8-K Report, Regulation FD Disclosure (Feb 18, 2026)
Cencora, Inc. (COR) has announced a significant strategic transaction involving its animal health business, MWI Animal Health. The company has entered into a definitive agreement to merge MWI with Covetrus, Inc. This transaction, which values MWI at an enterprise value of $3.5 billion, represents a pivotal step in reshaping Cencora's business focus and aims to unlock value for shareholders. The deal structure includes substantial upfront cash and equity in the combined entity, positioning Cencora for potential future upside while divesting a key segment. The merger is expected to provide Cencora with $1.25 billion in upfront cash and significant equity ownership (approximately 34.3%) in the indirect parent of Covetrus, CVET TopCo, LP, through preferred and common units valued at $2.25 billion. This cash infusion will likely bolster Cencora's financial flexibility, while the equity stake offers participation in the growth of the combined animal health business. The transaction is subject to customary closing conditions, including regulatory approvals, and is anticipated to be a key event for Cencora's strategic direction and financial profile.
Cencora, Inc. 8-K Report, Material Agreement (Feb 13, 2026)
Cencora, Inc. (COR) has filed an 8-K report detailing the successful closing of a $3.0 billion aggregate principal amount senior notes offering on February 13, 2026. This offering comprises multiple tranches with varying interest rates and maturity dates, ranging from 3.950% notes due 2029 to 5.650% notes due 2056. The proceeds from this significant debt issuance will be used for general corporate purposes, though specific use cases are not detailed in this filing. The issuance represents a substantial capital raise for Cencora, impacting its debt structure and financial leverage. Investors should note that these notes are unsecured and unsubordinated, ranking equally with existing unsecured and unsubordinated debt, but are structurally subordinated to all debt and liabilities of the company's subsidiaries. The indentures governing these notes include covenants related to liens, sale and leaseback transactions, and mergers, alongside standard events of default. This filing provides detailed information on the terms, interest rates, maturity dates, and redemption provisions for each series of notes.
Cencora, Inc. 8-K Report, Regulation FD Disclosure (Feb 11, 2026)
Cencora, Inc. (COR) has announced the pricing of a significant senior notes offering totaling $2.5 billion across multiple tranches with varying maturity dates and coupon rates. These notes include $500 million in 3.950% Senior Notes due 2029, $500 million in 4.250% Senior Notes due 2030, $500 million in 4.600% Senior Notes due 2033, $1 billion in 4.900% Senior Notes due 2036, and $500 million in 5.650% Senior Notes due 2056. The company expects to receive approximately $2.98 billion in net proceeds from this offering, after deducting underwriting discounts and expenses.
Cencora, Inc. 8-K Report, Corporate Update (Feb 10, 2026)
Cencora, Inc. (COR) has filed an 8-K to revise the presentation of its financial information within its previously filed 2025 Form 10-K. This revision is a result of a strategic review that led to a reorganization of its reporting structure, effective from the first quarter of fiscal year 2026. The company has moved to a new reporting structure consisting of three components: U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. Healthcare Solutions segment now includes U.S. Human Health (excluding legacy U.S. Consulting Services), while International Healthcare Solutions encompasses Alliance Healthcare, Innomar, World Courier, and specific components of Pharmalex. The 'Other' category, not considered a reportable segment, includes businesses for which strategic alternatives are being explored, such as MWI Animal Health, Profarma, U.S. Consulting Services, and remaining Pharmalex components. This filing updates specific sections of the 2025 Form 10-K to reflect this new segment alignment, though it does not amend or restate the audited consolidated financial statements themselves.
Cencora, Inc. 8-K Report, Financial Results (Feb 4, 2026)
Cencora, Inc. (COR) has filed a Form 8-K to disclose significant events occurring around the end of January and early February 2026. The most impactful news for investors is the company's acquisition of a majority stake in OneOncology for approximately $4.6 billion in cash, funded by new debt. This strategic move is expected to integrate OneOncology's operations into Cencora's U.S. Healthcare Solutions segment, signaling an expansion in the oncology physician services platform. Additionally, the filing announces the release of Cencora's earnings for the fiscal quarter ended December 31, 2025, with details provided in an attached news release. Investors should pay close attention to the financial performance reported for this quarter and the strategic implications of the OneOncology acquisition, particularly its impact on the company's debt structure and future growth within the U.S. Healthcare Solutions segment.
View all 8-K filings →